Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

JRCT ID: jRCT2031210404

Registered date:01/11/2021

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Non-small cell lung cancer
• Date of first enrollment: 01/11/2021
• Target sample size: 500
• Study type: Observational

Outcome(s)

Primary Outcome

Number of Participants with Adverse Events Related to Interstitial Lung Disease
Time Frame; Up to 1 year
An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

• Secondary Outcome: None

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer.
• Exclude criteria: Participants who has a history of hypersensitivity to any component of brigatinib.

Related Information

• Primary Sponsor: Contact for Clinical Trial Information